This is a working overview of angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-20 and is reviewed periodically as new material appears.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
On 7 August 2013, President Saakashvili said in an interview with Rustavi 2 TV that "the worst time for Georgia to engage in [military actions] was summer of 2008 and Russians knew it very well." Saakashvili said he offered Vladimir Putin in February 2008 to give up Georgia's NATO aspirations in exchange for Russia's help in restoring Georgia's control over the breakaway territories and that Georgia would endorse Russia's regional interests, but Putin refused by saying, "We do not exchange your territories for your geopolitical orientation." Saakashvili said that when he complained to Putin about escalation in the South Ossetian conflict zone, Putin threatened that the situation would even further deteriorate. Saakashvili said that Condoleezza Rice was assuring him in 2008 that there would be no war while Frank-Walter Steinmeier, German foreign minister, was the first to warn him about impending Russian attack. Saakashvili commented about the end of war in August 2008, "Eventually it was diplomacy and the U.S. sixth fleet that stopped Russia;" In March 2014, former president of Georgia, Mikheil Saakashvili wrote in The Washington Post, "Almost every Western politician to whom my government raised concerns in [July 2008] said that Russia would not attack and urged us to keep calm and not react to Russian moves." Saakashvili published an article in The Guardian where he wrote that "if the west had reacted properly to Georgia, Ukraine would never have happened." The Tagliavini Commission and actions of the EU emboldened Putin to act against Ukraine.
Capstone Project MS degree: MS degree in pharmaceutical sciences with emphasis in cosmetic science (30 credit hours) Graduate Certificate (GC) in Cosmetic Science: 12 credit hours covering skin and hair science as well as formulation science MS and PhD degrees: intensive research-based MS and PhD degrees in pharmaceutical science with emphasis in cosmetic science (on-site at Cincinnati) Courses for non-matriculated students: Online courses are available to non-matriculated students who have not applied for acceptance into the GC or MS Programs (a maximum of six (6) semester credit hours may be transferred to either program upon matriculation). The graduate programs in cosmetic science grew from 17 students in 2013 to 96 students in 2017.
=== Sensitivity === Detection limit is defined as the lowest amount of explosive matter a detector can detect reliably. It is expressed in terms of nano-grams (ng), pico-grams (pg) or femto-grams (fg) with fg being better than pg better than ng. It can also be expressed in terms of parts per billion (ppb), parts per trillion (ppt) or parts per quadrillion (ppq). Sensitivity is important because most explosives have a low vapor pressure . The detector with the highest sensitivity is the best in detecting vapors of explosives reliably.
Sources: en.wikipedia.org
== External links == FSL Constructs: A Simple Method for Modifying Cell/Virion Surfaces with a Range of Biological Markers Without Affecting their Viability – Journal of Visualised Experiments (JOVE) free video article [1] kodecyte.org - the academic resource for Kode Technology
It separately killed Davoud Alizadeh, the commander of the Quds Force's Lebanon Corps, in Tehran. In the night, Hezbollah fired rockets at Tel Aviv and Haifa. By 4 March, more than 300,000 southern Lebanese residents had been displaced due to the conflict. Israeli strikes hit residential areas in Beirut and eastern Lebanon, killing at least 11 people. Two Israeli soldiers were wounded in Lebanon after Hezbollah claimed to have struck a Merkava tank in Houla. On 6 March, a Hezbollah rocket strike in northern Israel injured eight soldiers, five seriously. Later that night, Israeli commandos raided Al-Nabi Shayth in an attempt to recover the remains of missing pilot Ron Arad, leading to a gunbattle that left three Lebanese soldiers dead. Simultaneous airstrikes in the area killed 41 people and injured 40 more. The Israelis withdrew without finding Arad's body. On 8 March, two Israeli soldiers were killed in a separate rocket attack in southern Lebanon. The following day, Hezbollah missiles struck a satellite communications center near Beit Shemesh and a daycare in Ramla in central Israel. On 1 April, an Israeli naval strike in Beirut killed Haj Youssef Ismail Hashem, the commander of Hezbollah's Southern Front. On 8 April, Israeli strikes killed 254 people and wounded more than 1,000 others in central Beirut. Israel Katz said that the strikes targeted hundreds of Hezbollah militants and command centers across Lebanon, in the group's largest blow since the pager attacks. On 16 April, President Trump announced that Israel and Lebanon agreed to a 10-day truce.
Data from high-throughput chromosome conformation capture experiments, such as Hi-C (experiment) and ChIA-PET, can provide information on the three-dimensional structure and nuclear organization of chromatin. Bioinformatic challenges in this field include partitioning the genome into domains, such as Topologically Associating Domains (TADs), that are organised together in three-dimensional space. Finding the structure of proteins is an important application of bioinformatics. The Critical Assessment of Protein Structure Prediction (CASP) is an open competition where worldwide research groups submit protein models for evaluating unknown protein models.
The difference between enzymatically active and inactive homologues has been noted (and in some cases, understood when comparing catalytically active and inactive proteins residing in recognisable families) for some time at the sequence level, owing to the absence of key catalytic residues. Some pseudoenzymes have also been referred to as 'prozymes' when they were analysed in protozoan parasites. The best studied pseudoenzymes reside amongst various key signalling superfamilies of enzymes, such as the proteases, the protein kinases, protein phosphatases and ubiquitin modifying enzymes. The role of pseudoenzymes as "pseudo scaffolds" has also been recognised and pseudoenzymes are now beginning to be more thoroughly studied in terms of their biology and function, in large part because they are also interesting potential targets (or anti-targets) for drug design in the context of intracellular cellular signalling complexes. Kinase Pseudokinase Phosphatome Protein phosphatase "Patrick Eyers - University of Liverpool". Liverpool.ac.uk. Retrieved 2017-01-16.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.